{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:57:25Z","timestamp":1780563445062,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005196","name":"Bureau of Justice Assistance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.japh.2020.12.012","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T18:51:41Z","timestamp":1610218301000},"page":"e86-e92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of gabapentin use in Kentucky after reclassification as a Schedule V controlled substance"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7203-8460","authenticated-orcid":false,"given":"GYeon","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetla","family":"Slavova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.japh.2020.12.012_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain - is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.japh.2020.12.012_bib3","first-page":"246","article-title":"Trends in gabapentin prescribing in a commercially insured U.S. Adult population, 2009\u20132016","volume":"26","author":"Pauly","year":"2020","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.japh.2020.12.012_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1526-4610.2001.111006119.x","article-title":"Efficacy of gabapentin in migraine prophylaxis","volume":"41","author":"Mathew","year":"2001","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.japh.2020.12.012_bib5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00004714-200012000-00004","article-title":"A\u00a0placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders","volume":"20","author":"Frye","year":"2000","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"19","key":"10.1016\/j.japh.2020.12.012_bib6","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/ajhp\/56.19.1939","article-title":"Gabapentin and lamotrigine in bipolar disorder","volume":"56","author":"Botts","year":"1999","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10.1016\/j.japh.2020.12.012_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00004714-200008000-00011","article-title":"Placebo-controlled study of gabapentin treatment of panic disorder","volume":"20","author":"Pande","year":"2000","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.japh.2020.12.012_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/10401230209147462","article-title":"New anticonvulsants: a review of applications for the management of substance abuse disorders","volume":"14","author":"Gentry","year":"2002","journal-title":"Ann Clin Psychiatry"},{"issue":"8","key":"10.1016\/j.japh.2020.12.012_bib9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/jama.2017.21547","article-title":"Gabapentin for chronic neuropathic pain","volume":"319","author":"Moore","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.japh.2020.12.012_bib10","first-page":"266","article-title":"Gabapentin use in a managed Medicaid population","volume":"8","author":"Hamer","year":"2002","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.japh.2020.12.012_bib11","article-title":"Gabapentin for off-label use: evidence-based or cause for concern?","volume":"12","author":"Peckham","year":"2018","journal-title":"Subst Abus"},{"issue":"6","key":"10.1016\/j.japh.2020.12.012_bib12","first-page":"559","article-title":"Examination of the evidence for off-label use of gabapentin","volume":"9","author":"Mack","year":"2003","journal-title":"J\u00a0Manag Care Pharm"},{"issue":"15","key":"10.1016\/j.japh.2020.12.012_bib13","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain--United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.japh.2020.12.012_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40264-017-0595-1","article-title":"All-cause and drug-related medical events associated with overuse of gabapentin and\/or opioid medications: a retrospective cohort analysis of a commercially insured US population","volume":"41","author":"Peckham","year":"2018","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.japh.2020.12.012_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.japh.2020.12.012_bib16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s13181-014-0384-5","article-title":"Clinical outcomes in newer anticonvulsant overdose: a poison center observational study","volume":"10","author":"Wills","year":"2014","journal-title":"J\u00a0Med Toxicol"},{"issue":"1","key":"10.1016\/j.japh.2020.12.012_bib17","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.7205\/MILMED-D-12-00301","article-title":"Gabapentin overdose in a military beneficiary","volume":"178","author":"Schauer","year":"2013","journal-title":"Mil Med"},{"issue":"7","key":"10.1016\/j.japh.2020.12.012_bib19","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.japh.2020.12.012_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/RMHP.S168504","article-title":"Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham","year":"2018","journal-title":"Risk Manag Healthc Policy"},{"key":"10.1016\/j.japh.2020.12.012_bib21","doi-asserted-by":"crossref","first-page":"107709","DOI":"10.1016\/j.drugalcdep.2019.107709","article-title":"Gabapentin drug misuse signals: a pharmacovigilance assessment using the FDA adverse event reporting system","volume":"206","author":"Vickers-Smith","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2020.12.012_bib22","doi-asserted-by":"crossref","unstructured":"Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update [e-pub ahead of print]. Drugs. https:\/\/doi.org\/10.1007\/s40265-020-01432-7, accessed December 4, 2020.","DOI":"10.1007\/s40265-020-01432-7"},{"issue":"8","key":"10.1016\/j.japh.2020.12.012_bib23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40261-017-0530-3","article-title":"Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population","volume":"37","author":"Peckham","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"7","key":"10.1016\/j.japh.2020.12.012_bib24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/15563650.2019.1687902","article-title":"Trends in gabapentin and baclofen exposures reported to U.S. poison centers","volume":"58","author":"Reynolds","year":"2020","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"10.1016\/j.japh.2020.12.012_bib25","first-page":"97","article-title":"Trends and patterns of opioid analgesic prescribing: regional and rural-urban variations in Kentucky from 2012 to 2015","volume":"35","author":"Luu","year":"2019","journal-title":"J\u00a0Rural Health"},{"key":"10.1016\/j.japh.2020.12.012_bib26","series-title":"Overdose Fatality Report","year":"2015"},{"issue":"3","key":"10.1016\/j.japh.2020.12.012_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.japh.2018.12.018","article-title":"Regulating gabapentin as a drug of abuse: a survey study of Kentucky community pharmacists","volume":"59","author":"Blackmer","year":"2019","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"6","key":"10.1016\/j.japh.2020.12.012_bib32","first-page":"280:e281","article-title":"Prescribing gabapentin off label: perspectives from psychiatry, pain and neurology specialists","volume":"145","author":"Fukada","year":"2012","journal-title":"Can Pharm J (Ott)"},{"issue":"6","key":"10.1016\/j.japh.2020.12.012_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217335","article-title":"Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: A double blind, randomized controlled trial","volume":"14","author":"Bulilete","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.japh.2020.12.012_bib34","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.injury.2018.06.002","article-title":"A\u00a0double-blind, randomized controlled trial of gabapentin vs. placebo for acute pain management in critically ill patients with rib fractures [published correction appears in Injury. 2019;50(7):1406]","volume":"49","author":"Moskowitz","year":"2018","journal-title":"Injury"},{"issue":"3","key":"10.1016\/j.japh.2020.12.012_bib35","first-page":"237","article-title":"The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis","volume":"31","author":"Hurley","year":"2006","journal-title":"Reg Anesth Pain Med"},{"issue":"6","key":"10.1016\/j.japh.2020.12.012_bib36","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1213\/01.ane.0000261517.27532.80","article-title":"Do surgical patients benefit from perioperative gabapentin\/pregabalin? A systematic review of efficacy and safety","volume":"104","author":"Tiippana","year":"2007","journal-title":"Anesth Analg"},{"issue":"7","key":"10.1016\/j.japh.2020.12.012_bib37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamasurg.2017.0898","article-title":"Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review","volume":"152","author":"Wick","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.japh.2020.12.012_bib39","first-page":"CD007938","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.japh.2020.12.012_bib40","first-page":"18m02291","article-title":"The association of gabapentin use and dose with substance use disorders prior to inpatient mental health treatment: a cross-sectional study","volume":"20","author":"Tomko","year":"2018","journal-title":"Prim Care Companion CNS Disord"},{"issue":"10","key":"10.1016\/j.japh.2020.12.012_bib41","first-page":"988","article-title":"Geographic variation in opioid prescribing in the U.S","volume":"13","author":"McDonald","year":"2012","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.japh.2020.12.012_bib42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugpo.2018.04.011","article-title":"Opioid-related mortality in rural America: geographic heterogeneity and intervention strategies","volume":"57","author":"Rigg","year":"2018","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.japh.2020.12.012_bib43","author":"Meit"},{"issue":"2","key":"10.1016\/j.japh.2020.12.012_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1037\/rmh0000064","article-title":"Substance use in rural central Appalachia: current status and treatment considerations","volume":"41","author":"Moody","year":"2017","journal-title":"Rural Ment Health"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319120306336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319120306336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:47:59Z","timestamp":1761544079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319120306336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1544319120306336"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2020.12.012","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of gabapentin use in Kentucky after reclassification as a Schedule V controlled substance","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2020.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}